Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy.

Targeting cancer neoantigens generated by tumor-exclusive somatic mutations is an attractive yet challenging strategy for the robust and specific elimination of tumor cells by cellular immunotherapy. In this issue of Cell, Wells et al. describe a consortium-based approach to optimize bioinformatics pipelines to sensitively and accurately predict immunogenic neoantigens from next-generation sequencing data.
Competing Interests: Declaration of Interests R.J.K., R.C.L., and N.P.R. are employed by and own equity in Lyell Immunopharma.
(Copyright © 2020 Elsevier Inc. All rights reserved.)